SBL
RNAM

Sargent Bickham Lagudis’s Avidity Biosciences RNAM Stock Holding History

Sargent Bickham Lagudis’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.22K Buy
+100
New +$1.49K ﹤0.01% 904

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sargent Bickham Lagudis's RNAM Position: Q4 2022 in Review

Sargent Bickham Lagudis opened a new position in Avidity Biosciences (RNAM) in Q4 2022: 100 shares worth $2.22K. The stake represents ﹤0.01% of the portfolio and ranks #904 among its holdings.

148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Sargent Bickham Lagudis held 100 shares of Avidity Biosciences worth $2.22K as of Q4 2022.
  • Avidity Biosciences was a new Sargent Bickham Lagudis position in Q4 2022.
  • Avidity Biosciences made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #904 holding.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.